| News

T3 Pharma raises over 25 million Swiss francs

22.07.2020

T3 Pharmaceuticals AG has closed its third financing round, raising over 25 million Swiss francs. The Basel-based startup has developed a bacterial cancer therapy that it now intends to progress to clinical trials.

T3 Pharmaceuticals (T3 Pharma) has successfully closed a third financing round, raising over 25 million Swiss francs. According to a press release, the financing was co-led by existing investors, including the Boehringer Ingelheim Venture FundReference Capital SAWille Finance AG and private investors. The company has raised over 40 million francs since it was founded in 2015.

A spin-off from the Biozentrum of the University of Basel, T3 Pharma has developed a novel cancer therapy using live bacteria. According to the University of Basel, the idea behind its approach combines two natural phenomena: that bacteria can colonize tumors and that certain bacteria can inject self-made protein molecules into human cells.

T3 Pharma intends to use the new funds to test its therapy in clinical studies, and a clinical trial in patients with solid tumors is planned to start in early 2021. The first phase will focus on safety and tolerability of the lead candidate and identification of the optimal dosage.

“This significant financing round comes at a pivotal moment for our company as we leverage the full potential of our proprietary platform and enter the clinic with our lead candidate,” said Simon Ittig, co-founder and CEO of T3 Pharma.

T3 Pharma has received support from the BaseLaunch accelerator and incubator program, which is run by the investment and innovation promotion agency Basel Area Business & Innovation.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Marija Plodinec: “I like a good challenge”
Basel Area Business & Innovation, Innovation, Switzerland Innovation Park

Marija Plodinec: “I like a good challenge”

As a CEO of a medtech startup looking for funding, you need to do two things extremely well: make sure...

Read More
Typewise presents new smartphone keyboard
Basel Area Business & Innovation, Innovation, Invest

Typewise presents new smartphone keyboard

The startup Typewise is presenting the third generation of its virtual keyboard for smartphones. Typewise 3.0 uses a new patented...

Read More
Basel Area starts new i4Challenge
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Basel Area starts new i4Challenge

The next round of the i4Challenge support program is getting underway. With this, Basel Area Business & Innovation is striving...

Read More
Basel Area shapes future health innovations
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Basel Area shapes future health innovations

A success factor for the Basel Area has been its steady transformation. From chemicals through the pharmaceutical industry to the...

Read More
Biggest successes in 2020 for biotechs in the Basel Area
Basel Area Business & Innovation, Innovation, Invest

Biggest successes in 2020 for biotechs in the Basel Area

Biotech companies in the Basel Area played a key role in the sector’s record performance in 2020. The latest Swiss...

Read More
New innovation campus to be named Switzerland Innovation Park Basel Area Main Campus
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

New innovation campus to be named Switzerland Innovation Park Basel Area Main Campus

A new innovation campus is currently under construction in Allschwil. This will be known as Switzerland Innovation Park Basel Area...

Read More
1 2 3 13

Do you have a question? We'd like to hear from you.